Renal Mass Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

141 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2017-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Collect valuable risk factor and quality of life data from Renal Cell Carcinoma patients and harness the latest technology to organize and analyze data.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

NCT03630536

Renal Cell Carcinoma

ACTIVE_NOT_RECRUITING

GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

NCT03819569

Small Renal Mass Kidney Tumor

COMPLETED NA

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

NCT00050752

Renal Tumor Histology Cutaneous Leiomyoma Kidney Cancer

RECRUITING

NCCN Renal Cell Registry

NCT02677337

Renal Cell Carcinoma

COMPLETED NA

Registry to Collect Health Information Related to Fibrolamellar Cancer

NCT04874519

Fibrolamellar Cancer FLC Liver Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RCC is a cancer that is poorly understood. The increase in both incidence and mortality rates for RCC, coupled with the lack of effective therapies for RCC beyond surgical excision, underscore the need for a better understanding of RCC tumor biology, immunology, and epidemiology. Such improved understanding could then be directly translated into new prevention strategies as well as improved patient care. Recently, the National Cancer Institute's Kidney Cancer Progress Review Group identified as top priorities for future research the need to better understand the mechanisms underlying known risk factors for kidney cancer; and examine tumor tissue to identify predictors of patient outcome and targets for therapy. In addition, the review group stressed that the leaders in renal cancer research over the next decade would be those institutions that could enroll large numbers of patients, collect valuable risk factor and quality of life data from these patients and harness the latest technology to organize and analyze data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Open

Group Type EXPERIMENTAL

questionnaire

Intervention Type OTHER

questionnaires given to all patients to assess risk factors and quality of life

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

questionnaire

questionnaires given to all patients to assess risk factors and quality of life

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a renal mass or a suspected metastatic lesion from a renal primary who have been treated or are going to be studied and or treated surgically at Mayo Clinic Arizona
* Patients must be 18 years of age or older
* Patients must be capable of and willing to sign an informed consent

Exclusion:

None

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No